{
    "ticker": "CLNN",
    "name": "Clene Nanomedicine, Inc.",
    "description": "Clene Nanomedicine, Inc. is a pioneering biotechnology company focused on the development of novel therapeutic solutions for neurodegenerative diseases. Established in 2014 and headquartered in Salt Lake City, Utah, Clene is dedicated to harnessing the power of nanotechnology to create innovative treatment options that address unmet medical needs. The company's unique approach involves the use of nanocrystal technology to develop therapeutics that can enhance the delivery of drugs to target tissues and improve patient outcomes. Clene's lead product candidate, CNM-Au8, is an oral formulation of gold nanocrystals designed to restore cellular energy metabolism and protect against oxidative stress in neurodegenerative conditions such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Clene aims to provide patients with effective therapies that can significantly improve their quality of life. With a strong commitment to scientific research and collaboration, Clene is actively engaged in clinical trials and partnerships to expedite the development of its promising drug candidates. The company's mission is to leverage its cutting-edge technology to transform the treatment landscape for neurological disorders and ultimately enhance patient care and outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Salt Lake City, Utah, USA",
    "founded": "2014",
    "website": "https://clenenanomedicine.com",
    "ceo": "Eric L. Hsu",
    "social_media": {
        "twitter": "https://twitter.com/clenenanomed",
        "linkedin": "https://www.linkedin.com/company/clene-nanomedicine/"
    },
    "investor_relations": "https://investors.clenenanomedicine.com",
    "key_executives": [
        {
            "name": "Eric L. Hsu",
            "position": "CEO"
        },
        {
            "name": "Samantha P. W. Hsu",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CNM-Au8"
            ]
        }
    ],
    "seo": {
        "meta_title": "Clene Nanomedicine, Inc. | Innovative Therapeutics for Neurodegenerative Diseases",
        "meta_description": "Explore Clene Nanomedicine, Inc., a biotechnology leader focused on nanotechnology-based therapeutics for neurodegenerative diseases like ALS and MS.",
        "keywords": [
            "Clene Nanomedicine",
            "Neurodegenerative Diseases",
            "ALS",
            "Multiple Sclerosis",
            "Nanotechnology",
            "CNM-Au8"
        ]
    },
    "faq": [
        {
            "question": "What does Clene Nanomedicine focus on?",
            "answer": "Clene Nanomedicine focuses on developing novel therapeutics for neurodegenerative diseases using nanotechnology."
        },
        {
            "question": "What is CNM-Au8?",
            "answer": "CNM-Au8 is Clene's lead product candidate, an oral formulation of gold nanocrystals aimed at treating ALS and MS."
        },
        {
            "question": "Where is Clene Nanomedicine headquartered?",
            "answer": "Clene Nanomedicine is headquartered in Salt Lake City, Utah, USA."
        },
        {
            "question": "When was Clene Nanomedicine founded?",
            "answer": "Clene Nanomedicine was founded in 2014."
        }
    ],
    "competitors": [
        "REGN",
        "SNY",
        "VRTX"
    ],
    "related_stocks": [
        "MRNA",
        "BNTX",
        "NVAX",
        "PFE"
    ]
}